microglial-targeted
Vigil’s TREM2-Targeted Alzheimer’s Treatment Advances to Phase II with Promising Early Results
TREM2, Alzheimer’s disease, Vigil Neuroscience, VG-3927, Phase II clinical trial, microglial-targeted therapeutics
Actionable Insights Powered by AI
TREM2, Alzheimer’s disease, Vigil Neuroscience, VG-3927, Phase II clinical trial, microglial-targeted therapeutics